Literature DB >> 22020330

SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.

C Canino1, F Mori, A Cambria, A Diamantini, S Germoni, G Alessandrini, G Borsellino, R Galati, L Battistini, R Blandino, F Facciolo, G Citro, S Strano, P Muti, G Blandino, M Cioce.   

Abstract

Here we show that pemetrexed-treated mesothelioma cells undergo accelerated senescence. This is characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-associated secretory phenotype). Conditioned media from senescent MPM (malignant pleural mesothelioma) cells trigger the emergence of EMT (epithelial-to-mesenchymal)-like, clonogenic and chemoresistant cell subpopulations, expressing high levels of ALDH (aldehyde dehydrogenase) activity (ALDH(bright) cells). We show by fluorescence-activated cell sorting of purified ALDH(bright) and ALDH(low) cells, that both cell-autonomous and cell-non-autonomous mechanisms converge to maintain the SASP-induced, EMT-like cell subpopulations. Chemoresistant ALDH(bright) cells exist within primary MPM specimens and enrichment for ALDH(bright) cells correlates with an earlier tumor onset into NOD/SCID mice. We show that RAS(v12) expression induces SASP-like changes in untransformed human mesothelial cells, and that p53 ablation increases the effect of RAS(v12) expression. We identify STAT3 activation as a crucial event downstream to SASP signaling. In fact, small hairpin RNA-mediated ablation of STAT3 deeply attenuates the induction of EMT genes and the increase of ALDH(bright) cells induced by SASP-cytokines. This strongly affects the chemoresistance of MPM cells in vitro and leads to anticancer effects in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020330     DOI: 10.1038/onc.2011.485

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

1.  HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

Authors:  Simona di Martino; Carla Azzurra Amoreo; Barbara Nuvoli; Rossella Galati; Sabrina Strano; Francesco Facciolo; Gabriele Alessandrini; Harvey I Pass; Gennaro Ciliberto; Giovanni Blandino; Ruggero De Maria; Mario Cioce
Journal:  Oncogene       Date:  2018-01-09       Impact factor: 9.867

2.  ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence.

Authors:  F Fausti; S Di Agostino; M Cioce; P Bielli; C Sette; P P Pandolfi; M Oren; M Sudol; S Strano; G Blandino
Journal:  Cell Death Differ       Date:  2013-08-09       Impact factor: 15.828

Review 3.  Senescence and apoptosis: dueling or complementary cell fates?

Authors:  Bennett G Childs; Darren J Baker; James L Kirkland; Judith Campisi; Jan M van Deursen
Journal:  EMBO Rep       Date:  2014-10-13       Impact factor: 8.807

Review 4.  Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment.

Authors:  Spiros A Vlahopoulos; Osman Cen; Nina Hengen; James Agan; Maria Moschovi; Elena Critselis; Maria Adamaki; Flora Bacopoulou; John A Copland; Istvan Boldogh; Michael Karin; George P Chrousos
Journal:  Cytokine Growth Factor Rev       Date:  2015-06-20       Impact factor: 7.638

5.  The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Authors:  Sara Cattelani; Giovanna Ferrari-Amorotti; Sara Galavotti; Raffaella Defferrari; Barbara Tanno; Samantha Cialfi; Jenny Vergalli; Valentina Fragliasso; Clara Guerzoni; Gloria Manzotti; Angela Rachele Soliera; Chiara Menin; Roberta Bertorelle; Heather P McDowell; Alessandro Inserra; Maria Luisa Belli; Luigi Varesio; Deborah Tweddle; Gian Paolo Tonini; Pierluigi Altavista; Carlo Dominici; Giuseppe Raschellà; Bruno Calabretta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

6.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.

Authors:  Ashkan Shahbandi; Sonia G Rao; Ashlyn Y Anderson; Wesley D Frey; Joy O Olayiwola; Nathan A Ungerleider; James G Jackson
Journal:  Cell Death Differ       Date:  2020-05-26       Impact factor: 15.828

8.  Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype.

Authors:  Lena Lau; Gregory David
Journal:  Expert Opin Ther Targets       Date:  2019-01-15       Impact factor: 6.902

9.  Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.

Authors:  Kuan-Chun Huang; Junzheng Yang; Michelle C Ng; Shu-Kay Ng; William R Welch; Michael G Muto; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2016-09-24       Impact factor: 9.162

10.  Redox control of the senescence regulator interleukin-1α and the secretory phenotype.

Authors:  Donald A McCarthy; Ryan R Clark; Toni R Bartling; Mohamed Trebak; J Andres Melendez
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.